Lytix Biopharma and UiT with exclusive agreement
Lytix Biopharma enters into an exclusive license agreement with the Arctic University of Norway (UiT) about drug candidates that combat cancer cells by stimulating the body’s own immune cells.
The Norwegian biotech company and Oslo Cancer Cluster member Lytix Biopharma has developed a new group of promising drug candidates together with a research team at the Arctic University of Norway (UiT). The drug candidates can combat cancer cells by stimulating the body’s own immune cells.
“Over the past year, we have achieved several key milestones with our most advanced drug candidate, LTX-315, and have successfully confirmed the unique potential of our technology platform. Through one of the joint projects with the scientific expertise at UiT, a set of new promising molecules have been discovered. This exclusive license agreement expands our overall product portfolio, which further demonstrates the robustness of our approach to this segment,” says CEO Øystein Rekdal at Lytix Biopharma in a press release from the company.
A broad collaboration
The drug candidates licensed have been developed in a collaboration between UiT and Lytix Biopharma, partly funded by the Norwegian Research Council and the Norwegian Cancer Society. A combined team from UiT, Norce, Oslo University Hospital and Institute Gustave Roussy in Paris have contributed to the project. Lytix Biopharma originally stems from the Arctic University in Tromsø.
This agreement grants Lytix Biopharma all rights to further develop and commercialize this new class of compounds.
Partnership with Aurelius Biotherapeutics
Lytix also forms a strategic partnership with the US-based specialist veterinary medicine company Aurelius Biotherapeutics to expedite the progression of the compounds that seem especially promising and suitable for the veterinary medicine market.
Aurelius Biotherapeutics now initiates further studies on this compound, to validate the initial data, and to refine its target product profile. Aurelius is currently also developing their own lead candidate, which now will be combined with the Lytix drug candidate.
Read more about the new partnerships in the press release from Lytix Biopharma. You can download it here.